PharmMental Group

PharmMental Group is a clinical-stage biotechnology company dedicated to the development of innovative treatments for central nervous system (CNS) and neuropsychiatric disorders. The company focuses on addressing high unmet medical needs in mental health, specifically targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). PharmMental utilizes a proprietary technology platform to identify and optimize therapeutic candidates, aiming for rapid-acting and long-lasting clinical effects. Their lead program, PMG-01, is currently being evaluated in clinical trials for its potential to provide superior outcomes compared to existing standards of care. The company is headquartered in London and maintains a strong focus on the global psychiatric pharmaceutical market.